Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.54
- Piotroski Score 2.00
- Grade Buy
- Symbol (ABUS)
- Company Arbutus Biopharma Corporation
- Price $3.95
- Changes Percentage (2.06%)
- Change $0.08
- Day Low $3.80
- Day High $3.96
- Year High $4.72
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $8.50
- High Stock Price Target $8.50
- Low Stock Price Target $8.50
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.44
- Trailing P/E Ratio -7.27
- Forward P/E Ratio -7.27
- P/E Growth -7.27
- Net Income $-72,849,000
Income Statement
Quarterly
Annual
Latest News of ABUS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Stuart Hogg pleads guilty to domestic abuse of estranged wife over five years
Former Scotland rugby captain Stuart Hogg admitted to abusing his estranged wife, Gillian Hogg, over five years. He pleaded guilty to a single charge of domestic abuse. Sentencing is scheduled for 5 D...
By The Guardian | 1 day ago -
New Documentary Shows Queen Camilla Fiercely Advocating for Domestic Abuse Survivors: 'She Helps Them to Feel Safe'
Queen Camilla's documentary, "Her Majesty The Queen: Behind Closed Doors," sheds light on her efforts to address domestic abuse. The film captures her empathy and advocacy for survivors, aiming to bre...
By PEOPLE.com | 2 days ago -
Native Woman Won $400,000 from Abuse Settlement, Then Vanished. Inside Family's Quest to Find Out What Happened
Legal reporter Samira Asma-Sadeque covers crime, immigration, mental health, and U.S. elections at PEOPLE....
By PEOPLE.com | 3 days ago
